keyword
https://read.qxmd.com/read/37989745/author-correction-diversity-oriented-synthesis-encoded-by-deoxyoligonucleotides
#1
Liam Hudson, Jeremy W Mason, Matthias V Westphal, Matthieu J R Richter, Jonathan R Thielman, Bruce K Hua, Christopher J Gerry, Guoqin Xia, Heather L Osswald, John M Knapp, Zher Yin Tan, Praveen Kokkonda, Ben I C Tresco, Shuang Liu, Andrew G Reidenbach, Katherine S Lim, Jennifer Poirier, John Capece, Simone Bonazzi, Christian M Gampe, Nichola J Smith, James E Bradner, Connor W Coley, Paul A Clemons, Bruno Melillo, C Suk-Yee Hon, Johannes Ottl, Christoph E Dumelin, Jonas V Schaefer, Ann Marie E Faust, Frédéric Berst, Stuart L Schreiber, Frédéric J Zécri, Karin Briner
No abstract text is available yet for this article.
November 21, 2023: Nature Communications
https://read.qxmd.com/read/37582753/diversity-oriented-synthesis-encoded-by-deoxyoligonucleotides
#2
JOURNAL ARTICLE
Liam Hudson, Jeremy W Mason, Matthias V Westphal, Matthieu J R Richter, Jonathan R Thielman, Bruce K Hua, Christopher J Gerry, Guoqin Xia, Heather L Osswald, John M Knapp, Zher Yin Tan, Praveen Kokkonda, Ben I C Tresco, Shuang Liu, Andrew G Reidenbach, Katherine S Lim, Jennifer Poirier, John Capece, Simone Bonazzi, Christian M Gampe, Nichola J Smith, James E Bradner, Connor W Coley, Paul A Clemons, Bruno Melillo, C Suk-Yee Hon, Johannes Ottl, Christoph E Dumelin, Jonas V Schaefer, Ann Marie E Faust, Frédéric Berst, Stuart L Schreiber, Frédéric J Zécri, Karin Briner
Diversity-oriented synthesis (DOS) is a powerful strategy to prepare molecules with underrepresented features in commercial screening collections, resulting in the elucidation of novel biological mechanisms. In parallel to the development of DOS, DNA-encoded libraries (DELs) have emerged as an effective, efficient screening strategy to identify protein binders. Despite recent advancements in this field, most DEL syntheses are limited by the presence of sensitive DNA-based constructs. Here, we describe the design, synthesis, and validation experiments performed for a 3...
August 15, 2023: Nature Communications
https://read.qxmd.com/read/37540536/motivational-interviewing-education-in-north-american-family-medicine-clerkships-a-cera-study
#3
JOURNAL ARTICLE
Denee J Moore, Melissa K Bradner, Scott M Strayer, Sally A Santen, Cherie Edwards, Rashelle B Hayes, Peter F Cronholm
BACKGROUND AND OBJECTIVES: Many health conditions are preventable or modifiable through behavioral changes. Motivational interviewing (MI) is an evidence-based communication technique that explores a patient's reasons for behavioral changes. This study assesses the current landscape of MI training in North American Family Medicine (FM) clerkships. METHODS: We analyzed data gathered as part of the 2022 Council of Academic Family Medicine's Educational Research Alliance (CERA) survey of FM clerkship directors (CDs)...
July 24, 2023: Family Medicine
https://read.qxmd.com/read/37451808/in-vitro-inactivation-of-sars-cov-2-by-ozonated-water-via-novel-hand-hygiene-device
#4
JOURNAL ARTICLE
Robert M Lubitz, Brian R Leon, K Nicole Bradner, Daniel J Romary, Sarah A Landsberger
AIMS: The COVID-19 Pandemic has heightened awareness of the need for novel surface disinfectants and hand-hygiene modalities. Ozone gas is an effective surface disinfectant, but toxicity limits its use in human applications. Ozonated water is a safer means to use ozone for disinfection, especially for human antisepsis. However, there are little data available regarding the effectiveness of ozonated water in eliminating severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). METHODS & RESULTS: This study utilizes a novel hand hygiene device that produces a stable ozone concentration of 0...
July 14, 2023: Journal of Applied Microbiology
https://read.qxmd.com/read/37237081/genome-scale-functional-genomics-identify-genes-preferentially-essential-for-multiple-myeloma-cells-compared-to-other-neoplasias
#5
JOURNAL ARTICLE
Ricardo de Matos Simoes, Ryosuke Shirasaki, Sondra L Downey-Kopyscinski, Geoffrey M Matthews, Benjamin G Barwick, Vikas A Gupta, Daphné Dupéré-Richer, Shizuka Yamano, Yiguo Hu, Michal Sheffer, Eugen Dhimolea, Olga Dashevsky, Sara Gandolfi, Kazuya Ishiguro, Robin M Meyers, Jordan G Bryan, Neekesh V Dharia, Paul J Hengeveld, Johanna B Brüggenthies, Huihui Tang, Andrew J Aguirre, Quinlan L Sievers, Benjamin L Ebert, Brian J Glassner, Christopher J Ott, James E Bradner, Nicholas P Kwiatkowski, Daniel Auclair, Joan Levy, Jonathan J Keats, Richard W J Groen, Nathanael S Gray, Aedin C Culhane, James M McFarland, Joshua M Dempster, Jonathan D Licht, Lawrence H Boise, William C Hahn, Francisca Vazquez, Aviad Tsherniak, Constantine S Mitsiades
Clinical progress in multiple myeloma (MM), an incurable plasma cell (PC) neoplasia, has been driven by therapies that have limited applications beyond MM/PC neoplasias and do not target specific oncogenic mutations in MM. Instead, these agents target pathways critical for PC biology yet largely dispensable for malignant or normal cells of most other lineages. Here we systematically characterized the lineage-preferential molecular dependencies of MM through genome-scale clustered regularly interspaced short palindromic repeats (CRISPR) studies in 19 MM versus hundreds of non-MM lines and identified 116 genes whose disruption more significantly affects MM cell fitness compared with other malignancies...
May 2023: Nature Cancer
https://read.qxmd.com/read/37121274/high-throughput-approaches-to-uncover-synergistic-drug-combinations-in-leukemia
#6
JOURNAL ARTICLE
Emma J Chory, Meng Wang, Michele Ceribelli, Aleksandra M Michalowska, Stefan Golas, Erin Beck, Carleen Klumpp-Thomas, Lu Chen, Crystal McKnight, Zina Itkin, Kelli M Wilson, David Holland, Sanjay Divakaran, James Bradner, Javed Khan, Berkley E Gryder, Craig J Thomas, Benjamin Z Stanton
We report a comprehensive drug synergy study in acute myeloid leukemia (AML). In this work, we investigate a panel of cell lines spanning both MLL-rearranged and non-rearranged subtypes. The work comprises a resource for the community, with many synergistic drug combinations that could not have been predicted a priori, and open source code for automation and analyses. We base our definitions of drug synergy on the Chou-Talalay method, which is useful for visualizations of synergy experiments in isobolograms, and median-effects plots, among other representations...
April 28, 2023: SLAS Discovery
https://read.qxmd.com/read/36863346/discovery-and-characterization-of-a-selective-ikzf2-glue-degrader-for-cancer-immunotherapy
#7
JOURNAL ARTICLE
Simone Bonazzi, Eva d'Hennezel, Rohan E J Beckwith, Lei Xu, Aleem Fazal, Anna Magracheva, Radha Ramesh, Artiom Cernijenko, Brandon Antonakos, Hyo-Eun C Bhang, Roxana García Caro, Jennifer S Cobb, Elizabeth Ornelas, Xiaolei Ma, Charles A Wartchow, Matthew C Clifton, Ry R Forseth, Bethany Hughes Fortnam, Hongbo Lu, Alfredo Csibi, Jennifer Tullai, Seth Carbonneau, Noel M Thomsen, Jay Larrow, Barbara Chie-Leon, Dominik Hainzl, Yi Gu, Darlene Lu, Matthew J Meyer, Dylan Alexander, Jacqueline Kinyamu-Akunda, Catherine A Sabatos-Peyton, Natalie A Dales, Frédéric J Zécri, Rishi K Jain, Janine Shulok, Y Karen Wang, Karin Briner, Jeffery A Porter, John A Tallarico, Jeffrey A Engelman, Glenn Dranoff, James E Bradner, Michael Visser, Jonathan M Solomon
Malignant tumors can evade destruction by the immune system by attracting immune-suppressive regulatory T cells (Treg) cells. The IKZF2 (Helios) transcription factor plays a crucial role in maintaining function and stability of Treg cells, and IKZF2 deficiency reduces tumor growth in mice. Here we report the discovery of NVP-DKY709, a selective molecular glue degrader of IKZF2 that spares IKZF1/3. We describe the recruitment-guided medicinal chemistry campaign leading to NVP-DKY709 that redirected the degradation selectivity of cereblon (CRBN) binders from IKZF1 toward IKZF2...
February 25, 2023: Cell Chemical Biology
https://read.qxmd.com/read/36121912/bridging-the-gap-to-translating-genome-wide-discoveries-into-therapies-to-prevent-and-treat-atherosclerotic-cardiovascular-disease
#8
EDITORIAL
Christopher J O'Donnell, James E Bradner
No abstract text is available yet for this article.
September 20, 2022: Circulation
https://read.qxmd.com/read/36056800/liquid-ozone-therapies-for-the-treatment-of-epithelial-wounds-a-systematic-review-and-meta-analysis
#9
REVIEW
Daniel J Romary, Sarah A Landsberger, K Nicole Bradner, Mirian Ramirez, Brian R Leon
Ozonated water and ozonated oils are emerging as potential therapies for wound care, but their efficacy has not been appropriately evaluated. The aim of this systematic review and meta-analysis was to evaluate the therapeutic potential of topical ozone in the treatment of mammalian wounds. A structured search of five scientific databases returned a total of 390 unique studies. Of these, 22 studies were included in this review. Four studies provided enough data to be included in a meta-analysis evaluating the time to complete wound healing...
September 3, 2022: International Wound Journal
https://read.qxmd.com/read/35843735/risk-of-cardiovascular-events-after-covid-19
#10
JOURNAL ARTICLE
Larisa G Tereshchenko, Adam Bishop, Nora Fisher-Campbell, Jacqueline Levene, Craig C Morris, Hetal Patel, Erynn Beeson, Jessica A Blank, Jg N Bradner, Michelle Coblens, Jacob W Corpron, Jenna M Davison, Kathleen Denny, Mary S Earp, Simeon Florea, Howard Freeman, Olivia Fuson, Florian H Guillot, Kazi T Haq, Morris Kim, Clinton Kolseth, Olivia Krol, Lisa Lin, Liat Litwin, Aneeq Malik, Evan Mitchell, Aman Mohapatra, Cassandra Mullen, Chad D Nix, Ayodele Oyeyemi, Christine Rutlen, Ashley E Tam, Inga Van Buren, Jessica Wallace, Akram Khan
We aimed to determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular (CV) events and all-cause mortality. We conducted a retrospective double cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection (COVID-19+ cohort) and its documented absence (COVID-19- cohort). The study investigators drew a simple random sample of records from all patients under the Oregon Health & Science University Healthcare (n = 65,585), with available COVID-19 test results, performed March 1, 2020 to September 13, 2020...
September 15, 2022: American Journal of Cardiology
https://read.qxmd.com/read/35083865/risks-of-ozonated-oil-and-ozonated-water-on-human-skin-a-systematic-review
#11
REVIEW
Brian R Leon, Daniel J Romary, Sarah A Landsberger, K Nicole Bradner, Mirian Ramirez, Robert M Lubitz
Ozonated water and oil are emerging as potential dermatologic therapeutics, particularly for the treatment of various wounds. However, the safety of these liquids has not been extensively studied. The aim of this systematic review was to evaluate the risks of ozonated liquids to human skin tissue based on the available literature. We completed a structured search of five scientific databases and identified 378 articles for consideration. Based on pre-established inclusion/exclusion criteria, nine studies were included in this review...
November 2022: International Wound Journal
https://read.qxmd.com/read/34650218/selective-targeting-of-myc-mrna-by-stabilized-antisense-oligonucleotides
#12
JOURNAL ARTICLE
Taylor Gill, Haichuan Wang, Raj Bandaru, Matthew Lawlor, Chenyue Lu, Linda T Nieman, Junyan Tao, Yixian Zhang, Daniel G Anderson, David T Ting, Xin Chen, James E Bradner, Christopher J Ott
MYC is a prolific proto-oncogene driving the malignant behaviors of numerous common cancers, yet potent and selective cell-permeable inhibitors of MYC remain elusive. In order to ultimately realize the goal of therapeutic MYC inhibition in cancer, we have initiated discovery chemistry efforts aimed at inhibiting MYC translation. Here we describe a series of conformationally stabilized synthetic antisense oligonucleotides designed to target MYC mRNA (MYCASOs). To support bioactivity, we designed and synthesized this focused library of MYCASOs incorporating locked nucleic acid (LNA) bases at the 5'- and 3'-ends, a phosphorothioate backbone, and internal DNA bases...
October 14, 2021: Oncogene
https://read.qxmd.com/read/34539163/discontinuation-of-transmission-precautions-for-covid-19-patients-polymerase-chain-reaction-diagnostics-patient-delays-and-cycle-threshold-values
#13
JOURNAL ARTICLE
Rahim A Jiwani, Yuxuan Mao, Adrian Pona, Evan Bradner, Jaffer Hussain, J Stephen Stalls, Paul Cook, Ashley Burch, Felix Afriyie, Jonathan Labbe, Ahmed Younes, Mai Badr, Elisabeth Lee, Rachel L Roper
BACKGROUND: The decision of when it is safe to discontinue transmission-based precautions for SARS-CoV-2 coronavirus disease 2019 (COVID-19) hospitalized patients has been controversial. The Centers for Disease Control and Prevention offered reverse transcriptase polymerase chain reaction (PCR) diagnostic test- or symptom-based guidelines. METHODS: A retrospective chart review of Vidant Health system, Eastern North Carolina, was conducted. Length of stay, days in isolation unit, and date appropriate for discharge or isolation discontinuation based on the symptom-based strategy were recorded...
September 2021: Infectious Diseases in Clinical Practice: IDCP
https://read.qxmd.com/read/34396987/bet-bromodomain-protein-inhibition-reverses-chimeric-antigen-receptor-extinction-and-reinvigorates-exhausted-t-cells-in-chronic-lymphocytic-leukemia
#14
JOURNAL ARTICLE
Weimin Kong, Alexander Dimitri, Wenliang Wang, In-Young Jung, Christopher J Ott, Maria Fasolino, Yan Wang, Irina Kulikovskaya, Minnal Gupta, Todd Yoder, Jamie E DeNizio, John K Everett, Erik F Williams, Jun Xu, John Scholler, Tyler J Reich, Vijay G Bhoj, Kathleen M Haines, Marcela V Maus, J Joseph Melenhorst, Regina M Young, Julie K Jadlowsky, Katherine T Marcucci, James E Bradner, Bruce L Levine, David L Porter, Frederic D Bushman, Rahul M Kohli, Carl H June, Megan M Davis, Simon F Lacey, Golnaz Vahedi, Joseph A Fraietta
Chimeric antigen receptor (CAR) T cells have induced remarkable antitumor responses in B cell malignancies. Some patients do not respond because of T cell deficiencies that hamper the expansion, persistence, and effector function of these cells. We used longitudinal immune profiling to identify phenotypic and pharmacodynamic changes in CD19-directed CAR T cells in patients with chronic lymphocytic leukemia (CLL). CAR expression maintenance was also investigated because this can affect response durability. CAR T cell failure was accompanied by preexisting T cell-intrinsic defects or dysfunction acquired after infusion...
August 16, 2021: Journal of Clinical Investigation
https://read.qxmd.com/read/34111271/report-of-the-national-institutes-of-health-sars-cov-2-antiviral-therapeutics-summit
#15
JOURNAL ARTICLE
Matthew D Hall, James M Anderson, Annaliesa Anderson, David Baker, Jay Bradner, Kyle R Brimacombe, Elizabeth A Campbell, Kizzmekia S Corbett, Kara Carter, Sara Cherry, Lillian Chiang, Tomas Cihlar, Emmie de Wit, Mark Denison, Matthew Disney, Courtney V Fletcher, Stephanie L Ford-Scheimer, Matthias Götte, Abigail C Grossman, Frederick G Hayden, Daria J Hazuda, Charlotte A Lanteri, Hilary Marston, Andrew D Mesecar, Stephanie Moore, Jennifer O Nwankwo, Jules O'Rear, George Painter, Kumar Singh Saikatendu, Celia A Schiffer, Timothy P Sheahan, Pei-Yong Shi, Hugh D Smyth, Michael J Sofia, Marla Weetall, Sandra K Weller, Richard Whitley, Anthony S Fauci, Christopher P Austin, Francis S Collins, Anthony J Conley, Mindy I Davis
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on November 6, 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for COVID-19, including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss SARS-CoV-2 targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics...
June 10, 2021: Journal of Infectious Diseases
https://read.qxmd.com/read/34107377/the-synergy-of-bet-inhibitors-with-aurora-a-kinase-inhibitors-in-mycn-amplified-neuroblastoma-is-heightened-with-functional-tp53
#16
JOURNAL ARTICLE
Joanna S Yi, Oscar Sias-Garcia, Nicole Nasholm, Xiaoyu Hu, Amanda Balboni Iniguez, Matthew D Hall, Mindy Davis, Rajarshi Guha, Myrthala Moreno-Smith, Eveline Barbieri, Kevin Duong, Jessica Koach, Jun Qi, James E Bradner, Kimberly Stegmaier, William A Weiss, W Clay Gustafson
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription. Here we sought to identify agents that synergize with BETi and to identify biomarkers of resistance. We previously performed a viability screen of ∼1,900 oncology-focused compounds combined with BET bromodomain inhibitors against MYCN-amplified NBL cell lines. Reanalysis of our screening results prominently identified inhibitors of aurora kinase A (AURKAi) to be highly synergistic with BETi...
June 6, 2021: Neoplasia: An International Journal for Oncology Research
https://read.qxmd.com/read/33861956/an-imid-inducible-degron-provides-reversible-regulation-for-chimeric-antigen-receptor-expression-and-activity
#17
Seth Carbonneau, Sujata Sharma, Liaomin Peng, Vaisakh Rajan, Dominik Hainzl, Martin Henault, Chian Yang, Jacob Hale, Janine Shulok, John Tallarico, Jeff Porter, Jennifer L Brogdon, Glenn Dranoff, James E Bradner, Marc Hild, Carla P Guimaraes
No abstract text is available yet for this article.
April 15, 2021: Cell Chemical Biology
https://read.qxmd.com/read/33547076/targeting-oncoproteins-with-a-positive-selection-assay-for-protein-degraders
#18
JOURNAL ARTICLE
Vidyasagar Koduri, Leslie Duplaquet, Benjamin L Lampson, Adam C Wang, Amin H Sabet, Mette Ishoey, Joshiawa Paulk, Mingxing Teng, Isaac S Harris, Jennifer E Endress, Xiaoxi Liu, Ethan Dasilva, Joao A Paulo, Kimberly J Briggs, John G Doench, Christopher J Ott, Tinghu Zhang, Katherine A Donovan, Eric S Fischer, Steven P Gygi, Nathanael S Gray, James Bradner, Jeffrey A Medin, Sara J Buhrlage, Matthew G Oser, William G Kaelin
Most intracellular proteins lack hydrophobic pockets suitable for altering their function with drug-like small molecules. Recent studies indicate that some undruggable proteins can be targeted by compounds that can degrade them. For example, thalidomide-like drugs (IMiDs) degrade the critical multiple myeloma transcription factors IKZF1 and IKZF3 by recruiting them to the cereblon E3 ubiquitin ligase. Current loss of signal ("down") assays for identifying degraders often exhibit poor signal-to-noise ratios, narrow dynamic ranges, and false positives from compounds that nonspecifically suppress transcription or translation...
February 2021: Science Advances
https://read.qxmd.com/read/33406420/functional-genomics-identify-distinct-and-overlapping-genes-mediating-resistance-to-different-classes-of-heterobifunctional-degraders-of-oncoproteins
#19
JOURNAL ARTICLE
Ryosuke Shirasaki, Geoffrey M Matthews, Sara Gandolfi, Ricardo de Matos Simoes, Dennis L Buckley, Joseline Raja Vora, Quinlan L Sievers, Johanna B Brüggenthies, Olga Dashevsky, Haley Poarch, Huihui Tang, Megan A Bariteau, Michal Sheffer, Yiguo Hu, Sondra L Downey-Kopyscinski, Paul J Hengeveld, Brian J Glassner, Eugen Dhimolea, Christopher J Ott, Tinghu Zhang, Nicholas P Kwiatkowski, Jacob P Laubach, Robert L Schlossman, Paul G Richardson, Aedin C Culhane, Richard W J Groen, Eric S Fischer, Francisca Vazquez, Aviad Tsherniak, William C Hahn, Joan Levy, Daniel Auclair, Jonathan D Licht, Jonathan J Keats, Lawrence H Boise, Benjamin L Ebert, James E Bradner, Nathanael S Gray, Constantine S Mitsiades
Heterobifunctional proteolysis-targeting chimeric compounds leverage the activity of E3 ligases to induce degradation of target oncoproteins and exhibit potent preclinical antitumor activity. To dissect the mechanisms regulating tumor cell sensitivity to different classes of pharmacological "degraders" of oncoproteins, we performed genome-scale CRISPR-Cas9-based gene editing studies. We observed that myeloma cell resistance to degraders of different targets (BET bromodomain proteins, CDK9) and operating through CRBN (degronimids) or VHL is primarily mediated by prevention of, rather than adaptation to, breakdown of the target oncoprotein; and this involves loss of function of the cognate E3 ligase or interactors/regulators of the respective cullin-RING ligase (CRL) complex...
January 5, 2021: Cell Reports
https://read.qxmd.com/read/33333026/an-imid-inducible-degron-provides-reversible-regulation-for-chimeric-antigen-receptor-expression-and-activity
#20
JOURNAL ARTICLE
Seth Carbonneau, Sujata Sharma, Liaomin Peng, Vaisakh Rajan, Dominik Hainzl, Martin Henault, Chian Yang, Jacob Hale, Janine Shulok, John Tallarico, Jeff Porter, Jennifer L Brogdon, Glenn Dranoff, James E Bradner, Marc Hild, Carla P Guimaraes
The recent development of successful CAR (chimeric antigen receptor) T cell therapies has been accompanied by a need to better control potentially fatal toxicities that can arise from adverse immune reactions. Here we present a ligand-controlled CAR system, based on the IKZF3 ZF2 β-hairpin IMiD-inducible degron, which allows for the reversible control of expression levels of type I membrane proteins, including CARs. Testing this system in an established mouse xenotransplantation model for acute lymphoblastic leukemia, we validate the ability of the CAR19-degron to target and kill CD19-positive cells displaying complete control/clearance of the tumor...
June 17, 2021: Cell Chemical Biology
keyword
keyword
113766
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.